HTLV-1
6
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
33%
2 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (6)
Darifenacin x Parasacral Transcutaneous Electric Nerve Stimulation for OAB in Patients Infected With Human T-Lymphotropic Virus 1
Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis
Sensorimotor Exercises in Virtual Reality Platform in Individuals With Human T-lymphotropic Virus
Urological Physical Therapy in HTLV-1 With Urinary Symptoms
Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa
Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases